Status:

COMPLETED

Optimal Detection of Atrial Fibrillation in TIA

Lead Sponsor:

Alfried Krupp Krankenhaus

Collaborating Sponsors:

Medtronic Bakken Research

Coordinating Centre for Clinical Trials Heidelberg

Conditions:

Atrial Fibrillation

Transient Ischemic Attack

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

Transient ischemic attack (TIA) is a common neurologic emergency. Although the detection of atrial fibrillation (AF) has identical consequences for preventive therapy in patients with ischemic stroke ...

Detailed Description

Transient ischemic attacks (TIA) are a common neurologic emergency. Clinical management guidelines recommend oral anticoagulation for TIA patients suffering from atrial fibrillation (AF). Therefore, a...

Eligibility Criteria

Inclusion

  • Eligibility Criteria:
  • Study Population Patients with a recent TIA will be enrolled during a period of approximately 24 months at participating European stroke centres. TIA patients may be enrolled after initial management as inpatients or outpatients. Consecutive screening and enrolment will be strongly encouraged and a screening log will be implemented at each site.
  • Inclusion Criteria
  • Written informed consent by patient.
  • Age ≥ 50 years.
  • TIA diagnosed by a stroke physician defined as rapidly developing clinical signs of focal or global disturbances of cerebral function, lasting less than 24 hours with no apparent non-vascular cause
  • 12-channel ECG available before enrolment
  • Brain imaging available before enrolment (CCT or cranial MRI)
  • Vascular imaging of cervical vessels performed
  • Enrolment within 28 days after TIA episode. Exclusion Criteria
  • Previously documented history of AF
  • Ischemic stroke within the last 6 months before enrolment
  • Pre-screening monitoring for cardiac arrhythmias lasting ≥72 hours
  • AF lasting \> 30 s on a 12 channel ECG or other ECG recording technique prior to enrolment
  • Life expectancy less than 1 year.
  • Significant stenosis \> 50% in intracranial or extracranial vessels which, in the opinion of the investigator, is the likely cause of the patients TIA.
  • Severely disabled patients (i.e. modified Rankin Score \>3)
  • Lack of therapeutic consequence in case of diagnosis of AF (e.g. other indication for long term anticoagulation
  • Pacemaker or Implanted Cardiac Defibrillator

Exclusion

    Key Trial Info

    Start Date :

    March 12 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 31 2025

    Estimated Enrollment :

    515 Patients enrolled

    Trial Details

    Trial ID

    NCT04075500

    Start Date

    March 12 2019

    End Date

    August 31 2025

    Last Update

    November 19 2025

    Active Locations (27)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 7 (27 locations)

    1

    Universitätsklinikum Aachen, Neurologie

    Aachen, Germany, 52074

    2

    Rhön Klinikum Campus Bad Neustadt

    Bad Neustadt an der Saale, Germany, 97616

    3

    Vivantes Klinikum Neukölln

    Berlin, Germany, 12351

    4

    Carl-Thiem-Klinikum Cottbus; Klinik für Neurologie

    Cottbus, Germany, 03048